0%
Print report
Variant interpretation report

ATM c.8921C>T, p.Pro2974Leu

NM_000051.4:c.8921C>T NP_000042.3:p.(Pro2974Leu) Missense · exon 62 View identifiers
Classification
Likely benign

Variant description:

The ATM NM_000051.4:c.8921C>T (NP_000042.3:p.(Pro2974Leu)) missense variant has previously been reported in somatic cancers (COSMIC; COSV99069711, n = 8 times). Experimental evidence: Variant-specific studies show reduced ATM phosphorylation and impaired DNA-repair rescue, while Sun et al. reports Functional in direct prime editing. Table S1 directly measures the variant as Functional with High confidence, but published assays report abnormal ATM activity and require human review. Based on available guidelines, this variant is considered to be Likely Benign.

Five-step scale from benign to pathogenic. This variant is likely benign. Select a step to read what it means.

Likely benign.A likely benign classification under the recorded framework.

In plain language

Gene-level background from the recorded interpretation.

About ATM

ATM encodes a kinase that acts as a master controller of the cellular DNA damage response: it detects double-strand breaks and coordinates DNA repair, cell cycle arrest, or apoptosis through downstream targets including p53, BRCA1, and CHK2. Loss-of-function mutations in both copies of ATM cause ataxia telangiectasia, an autosomal recessive disorder characterized by neurological problems, immune deficiency, and cancer predisposition. ATM functions as a tumor suppressor: individuals with ataxia telangiectasia are prone to childhood lymphomas, leukemias, and breast cancer, while carriers of a single altered copy have increased risk of breast, pancreatic, prostate, and other cancers. Somatic ATM mutations also occur in lymphoid malignancies and solid tumors, and ATM-deficient cancers are often especially sensitive to DNA-damaging treatments.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is ClinGen ATM VCEP v1.6. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 2 Benign evidence criteria: 3
Pathogenic criteria applied · 2
PS3Supporting
PS3 · supporting

Met, Supporting: variant-specific studies show reduced ATM phosphorylation and impaired DNA-repair rescue, while Sun et al. reports Functional in direct prime editing.

PS4Strong
PS4 · strong

Met, Strong: 13/7,204 cases versus 0/9,593 controls, p=1.7 x 10^-5 <= .05, corrected OR=36.018, and lower 95% CI=2.141 >=1.5.

Benign criteria applied · 3
BS1Strong
BS1 · strong

Met, Strong: gnomAD v4.1 grpmax Filtering AF is 0.193551%, exceeding the VCEP BS1 threshold of >0.05%.

BS3Supporting
BS3 · supporting

Met, Supporting: Table S1 directly measures the variant as Functional with High confidence, but published assays report abnormal ATM activity and require human review.

BP4Supporting
BP4 · supporting

Met: missense REVEL 0.148 is at or below the VCEP BP4 cutoff of <=0.249.

Recorded classification: Likely benign

Likely Benign: BS1 (strong) independently satisfies ATM VCEP Rule20; BS3 and BP4 (supporting) also satisfy Rule19.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

gnomAD v4.1
gnomAD v2.1
Population frequency
158 / 1,614,118 alleles

gnomAD v4.1: 158 / 1,614,118 alleles. Recorded AF 9.78863e-05. Recorded homozygote count 0.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 7.77946e-05; MAF= 0.00778%, 22/282796 alleles, homozygotes = 0) and has highest observed frequency in the East Asian population (AF= 0.000400962; MAF= 0.04010%, 8/19952 alleles, homozygotes = 0); grpmax FAF= 0.0001781.

gnomAD-Canada

This variant is present in gnomAD-Canada v1.0 (AF= 0.00016291951775822744, 3/18414 alleles, homozygotes = 0).

No screenshot for this evidence
REVEL score
0.148 recorded score

Recorded REVEL score: 0.148. Refer to the recorded PP3/BP4 rationale for interpretation.

ClinVar submissions
18 reported laboratory submissions

13 Uncertain significance · 3 Likely benign · 2 Benign. ClinVar API review status: criteria provided, conflicting classifications.

Context only ClinVar ↗
Functional evidence
Statement recorded

OncoKB identified variant-specific curated literature and context relevant to functional review; biological-effect context: Likely Loss-of-function; curated oncogenicity label: Likely Oncogenic.

COSMIC
Cancer Hotspots
Somatic evidence
8 recorded samples

This variant has previously been reported in somatic cancers (COSMIC; COSV99069711, n = 8 times).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.

For specialists

Technical detail

ACMG/AMP criteria under ClinGen ATM VCEP v1.6, with the data and sources behind each one.

28 criteria with recorded statuses: 5 met · 6 not met · 0 not assessed · 17 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

Functional evidence is discordant: the governing Sun et al. Table S1 row assigns direct prime-editing Functional/High/No, while two exact-variant published studies report abnormal ATM-specific functional readouts.

PS3 and BS3 are both recorded at Supporting with needs_human_review=true because the available functional sources point in opposite directions.

PS4 is met at Strong because the exact variant has direct case-control evidence satisfying the VCEP's p-value and enrichment thresholds.

PP4, PP5, BP5, and BP6 are not applicable because the ATM VCEP CSPEC explicitly marks each criterion Not Applicable.

PM3 is not met because the exact-variant report does not describe an A-T proband or a pathogenic ATM variant in trans.

BP2 is not met because the report does not establish cis/trans pathogenic-variant status in a qualifying unaffected adult.

The governing ATM_PM3_BP2_1.6.pdf file was searched for c.8921C>T, p.Pro2974Leu, and p.P2974L without a matching entry.

PP3 is not met because neither the VCEP missense REVEL threshold nor its qualifying SpliceAI threshold is reached.

BP4 is met at Supporting strength through the VCEP missense REVEL path; the low SpliceAI score is corroborative and not double-counted.

BP7 is not applicable because the variant is exonic missense rather than synonymous or deep intronic.

Met · 5

PS3 SupportingVCEPMet, Supporting: variant-specific studies show reduced ATM phosphorylation and impaired DNA-repair rescue, while Sun et al. reports Functional in direct prime editing. Details ▾Hide ▴
Reasoning

The exact variant is functionally abnormal in variant-specific published assays. Oguchi et al. (PMID:12511424) tested ATM 8921C>T/p.Pro2974Leu and reported only partial rescue of radiosensitivity, approximately 60% reduction in in-vitro p53-Ser15 phosphorylation activity, and reduced irradiation-induced p53-Ser15 phosphorylation. Li et al. (PMID:31160347) independently studied ATM rs139379666/p.P2974L and reported failure to restore homologous-recombination repair, increased gamma-H2AX-positive cells after irradiation (43% versus 33%, P < 0.05), and reduced phosphorylation of downstream ATM substrates. These findings support PS3 at Supporting because an ATM-specific functional feature is not rescued, but the exact VCEP-approved assay-calibration file contains no variant-specific row for c.8921C>T, p.Pro2974Leu, or p.P2974L and therefore cannot establish a higher VCEP-calibrated strength. Sun et al. 2025 Table S1 assigns this variant Classification=Functional, Confidence=High, DeepATM_predicted=No, which is a conflicting direct prime-editing result; human review is required.

VCEP rule
Use when a variant fails to rescue an ATM specifc feature, only (e.g. phosphorylation of ATM-specific targets). Do not use for radiosensitivity-only as that is not a feature specific to ATM deficiency
Evidence considered
  • ClinGen ATM v1.6 PS3 rule: use Supporting when a variant fails to rescue an ATM-specific feature only, including phosphorylation of ATM-specific targets; do not use radiosensitivity-only evidence.
  • Oguchi et al., PMID:12511424, Results sections "Biologic activity of 8921T ATM" and "Dominant-negative effect of the 8921T mutation": exact 8921C>T/p.Pro2974Leu variant; partial radiosensitivity rescue, approximately 60% less in-vitro p53-Ser15 phosphorylation, and reduced irradiation-induced p53-Ser15 phosphorylation.
  • Li et al., PMID:31160347, ATM-knockdown U2OS and ATM-knockout SK-BR3 assays: exact rs139379666/p.P2974L variant failed to restore homologous-recombination repair, produced 43% versus 33% gamma-H2AX-positive cells after 10 Gy irradiation (P < 0.05), and reduced downstream-substrate phosphorylation.
  • Sun et al. 2025 Supplementary Table S1, matching row c.8921C>T / P2974L: Classification=Functional, Confidence=High, DeepATM_predicted=No; the row is a direct prime-editing measurement and conflicts with the abnormal results above.
  • The VCEP approved functional-assay file was searched for c.8921C>T, p.Pro2974Leu, and p.P2974L; no variant-specific entry was found.
Still missing
  • No entry for c.8921C>T, p.Pro2974Leu, or p.P2974L was found in clingen_hbop_atm_supplementary_tables_1_and_2_v1.xlsx; that file is an assay-methodology and strength-calibration table rather than a variant-results table.
  • The available variant-specific functional studies are not the three assays named in the VCEP approved-assay calibration table, so a higher VCEP-calibrated PS3 strength cannot be assigned from that table.
Sources
PS4 StrongVCEPMet, Strong: 13/7,204 cases versus 0/9,593 controls, p=1.7 x 10^-5 <= .05, corrected OR=36.018, and lower 95% CI=2.141 >=1.5. Details ▾Hide ▴
Reasoning

The ATM VCEP rule requires a case-control study with p-value <=.05 and either odds ratio, hazard ratio, or relative risk >=2, or lower 95% CI >=1.5. PMID:31160347 directly studied rs139379666/p.P2974L in Chinese breast-cancer cohorts: 13 of 7,204 cases carried the T allele and 0 of 9,593 controls did; the paper reports p=1.7 x 10^-5. This is a case-control comparison even though the uncorrected odds ratio is unbounded because no control carried the allele. Applying a Haldane-Anscombe 0.5-cell correction gives OR=36.018 and a 95% Wald CI of 2.141-606.019. The explicit threshold checks are p=1.7 x 10^-5 <= .05? yes; corrected OR=36.018 >=2? yes; lower 95% CI=2.141 >=1.5? yes. The paper's abstract and full text were verified, including the exact variant and case/control counts. PS4 Strong is met.

VCEP rule
Case-control studies; p-value ≤.05 **and** (Odds ratio, hazard ratio, or relative risk ≥2 **or** lower 95% CI ≥1.5).
Evidence considered
  • ClinGen HBOP ATM VCEP v1.6 CSPEC PS4 entry: Case-control studies; p-value <=.05 and (Odds ratio, hazard ratio, or relative risk >=2 or lower 95% CI >=1.5).
  • PMID:31160347, Results/Table 1 and abstract: ATM rs139379666/p.P2974L T allele occurred in 13/7,204 Chinese breast-cancer cases and 0/9,593 controls, with overall P=1.7 x 10^-5.
  • Computed from the reported counts using a Haldane-Anscombe 0.5-cell correction for the zero-control cell: OR=36.018146; 95% Wald CI=2.140704-606.018821.
  • Explicit operator checks: p=1.7 x 10^-5 <= .05? yes; corrected OR=36.018146 >=2? yes; lower 95% CI=2.140704 >=1.5? yes.
Sources
BS1 StrongVCEPMet, Strong: gnomAD v4.1 grpmax Filtering AF is 0.193551%, exceeding the VCEP BS1 threshold of >0.05%. Details ▾Hide ▴
Reasoning

The ATM VCEP defines BS1 as Grpmax Filtering AF >.05% in gnomAD. Using the default all-comers gnomAD source because the VCEP does not specify a non-cancer or exome-only source, the gnomAD v4.1 grpmax Filtering AF is 0.00193551 (0.193551%), exceeding 0.05%; therefore BS1 is met at Strong strength.

VCEP rule
Grpmax Filtering AF **>.05%** in gnomAD
Evidence considered
  • ClinGen HBOP ATM VCEP v1.6 CSPEC BS1 rule: Grpmax Filtering AF >.05% in gnomAD.
  • gnomAD v4.1 all-comers: grpmax FAF 0.00193551 (0.193551%); highest subpopulation East Asian AF 0.0022949066440889443 (0.22949%), 103/44882 alleles, homozygotes 0.
  • The VCEP rule does not specify a non-cancer or exome-only population source, so the default all-comers gnomAD v4.1 entry was used.
Sources
BS3 SupportingVCEPMet, Supporting: Table S1 directly measures the variant as Functional with High confidence, but published assays report abnormal ATM activity and require human review. Details ▾Hide ▴
Reasoning

Sun et al. 2025 Supplementary Table S1 contains the exact row c.8921C>T / P2974L with Classification=Functional, Confidence=High, and DeepATM_predicted=No. Under the VCEP-declared curation policy for this table, this is a direct prime-editing measurement and Functional maps to BS3_Supporting. The result conflicts with variant-specific published functional studies: Oguchi et al. (PMID:12511424) reported impaired ATM-specific p53 phosphorylation and only partial radiosensitivity rescue, while Li et al. (PMID:31160347) reported impaired homologous-recombination repair, increased irradiation-associated gamma-H2AX, and reduced downstream-substrate phosphorylation. Therefore BS3 is met at Supporting from the governing Table S1 pre-assigned code, but the discordant functional evidence requires human review. The separate VCEP approved-assay calibration file has no entry for this variant.

VCEP rule
Use when a variant rescues EITHER an ATM specifc feature OR rescues radiosensitivity.
Evidence considered
  • ClinGen ATM v1.6 BS3 rule: use Supporting when a variant rescues either an ATM-specific feature or radiosensitivity.
  • Sun et al. 2025 Supplementary Table S1, matching row c.8921C>T / P2974L: Classification=Functional, Confidence=High, DeepATM_predicted=No. The VCEP-declared table policy maps this direct prime-editing Functional result to BS3_Supporting.
  • Oguchi et al., PMID:12511424, exact 8921C>T/p.Pro2974Leu: approximately 60% less in-vitro p53-Ser15 phosphorylation, reduced irradiation-induced p53-Ser15 phosphorylation, and only partial radiosensitivity rescue.
  • Li et al., PMID:31160347, exact rs139379666/p.P2974L: failed homologous-recombination repair rescue, 43% versus 33% gamma-H2AX-positive cells after 10 Gy irradiation (P < 0.05), and reduced downstream-substrate phosphorylation.
  • The VCEP approved functional-assay file was searched for c.8921C>T, p.Pro2974Leu, and p.P2974L; no variant-specific entry was found.
Still missing
  • No entry for c.8921C>T, p.Pro2974Leu, or p.P2974L was found in clingen_hbop_atm_supplementary_tables_1_and_2_v1.xlsx; that file is an assay-methodology and strength-calibration table rather than a variant-results table.
  • The discordant Table S1 Functional result and variant-specific abnormal published assays are not reconciled by the available VCEP materials.
Sources
BP4 SupportingVCEPMet: missense REVEL 0.148 is at or below the VCEP BP4 cutoff of <=0.249. Details ▾Hide ▴
Reasoning

The ATM VCEP BP4 rule provides a missense path using REVEL <=0.249 and a splicing path using SpliceAI <=0.1. This is a missense variant with REVEL 0.148, which directly meets the VCEP missense cutoff; SpliceAI maximum delta score 0.006 also meets the VCEP no-predicted-splicing-impact cutoff. The evidence is counted once for BP4, using the named missense predictor as the decisive path. The exact Sun et al. Table S1 row for c.8921C>T/p.P2974L reports REVEL 0.148 and Classification Functional, Confidence High, DeepATM_predicted No; the functional classification is not treated as a separate BP4 prediction.

VCEP rule
* Missense: REVEL score **≤.249** * Splicing: No predicted impact via splicing (SpliceAI **≤0.1**).
Evidence considered
  • The ATM VCEP BP4 rule states: missense REVEL <=0.249; alternatively, no predicted splicing impact via SpliceAI <=0.1.
  • Local REVEL lookup for NM_000051.4:c.8921C>T, p.(Pro2974Leu) reports score 0.148, meeting the missense BP4 threshold.
  • SpliceAI reports maximum delta score 0.006, also meeting the VCEP no-predicted-impact threshold; this is corroborative and not double-counted with REVEL.
  • Sun et al. 2025 Supplementary Table S1, exact row c.8921C>T / P2974L / exon_62: REVEL 0.148; Classification Functional; Confidence High; DeepATM_predicted No.
Sources

Not met · 6 · evaluated, threshold not reached

PS1 VCEPNot met: ATM PS1 requires a previously established pathogenic variant with the same amino-acid change, but ATM_PS1_1.6 has no c.8921C>T, p.Pro2974Leu, or p.P2974L entry. Details ▾Hide ▴
Reasoning

The ATM VCEP PS1 rule requires the same amino acid change as a previously established pathogenic variant and, for missense changes, splice defects to be ruled out for both alterations. The governing ATM_PS1_1.6 file was searched for c.8921C>T, p.Pro2974Leu, and p.P2974L; it contains no entry for this variant. The reviewed literature reports this exact variant, including functional and clinical observations, but does not provide a distinct previously established pathogenic comparator required by PS1. Therefore PS1 is not met.

VCEP rule
Same amino acid change as a previously established pathogenic variant regardless of nucleotide change ... • Missense: This rule may be applied only when a splice defect is ruled out for both alterations either by RNA analysis and/or in silico splice predictions
Evidence considered
  • ATM_PS1_1.6.pdf: the PS1 guide defines PS1 as the same amino acid change as a previously established pathogenic variant regardless of nucleotide change and requires splice-defect exclusion for missense alterations.
  • ATM_PS1_1.6.pdf.txt was searched for c.8921C>T, p.Pro2974Leu, and p.P2974L; no matching variant entry was found.
  • PMID:12511424 reports the exact 8921C>T/p.Pro2974Leu variant with partial functional rescue and reduced p53-Ser15 phosphorylation, but it is not a distinct same-amino-acid reference variant for PS1.
  • PMID:31160347 reports the exact ATM P2974L variant and functional impairment, but it is not a distinct same-amino-acid reference variant for PS1.
Still missing
  • No qualifying reference-variant entry for c.8921C>T, p.Pro2974Leu, or p.P2974L was found in ATM_PS1_1.6.pdf.txt.
Sources
PM2 VCEPNot met: the highest gnomAD v4.1 subpopulation AF is 0.22949% (103/44882), exceeding the VCEP PM2 threshold of <=0.001%. Details ▾Hide ▴
Reasoning

The ATM VCEP defines PM2 Supporting as frequency <=.001% in the gnomAD subpopulation with the highest frequency, with an exception for a singleton in one subpopulation only. Using the default all-comers gnomAD source because the VCEP does not specify a non-cancer or exome-only source, gnomAD v4.1 has a highest-subpopulation East Asian AF of 0.0022949066440889443 (0.22949%; 103/44882 alleles), which exceeds .001% and is not a singleton; therefore PM2 is not met.

VCEP rule
Frequency **≤.001%** in gnomAD subpopulation with the highest frequency Exception: If >0.001% but n=1 in a single subpopulation (not present in any other subpopulation), that is sufficiently rare and PM2\_supporting would apply.
Evidence considered
  • ClinGen HBOP ATM VCEP v1.6 CSPEC PM2 rule: Frequency <=.001% in gnomAD subpopulation with the highest frequency; exception applies only if >0.001% but n=1 in a single subpopulation and absent from every other subpopulation.
  • gnomAD v4.1 all-comers: highest subpopulation is East Asian with AF 0.0022949066440889443 (0.22949%), AC 103, AN 44882, homozygotes 0; grpmax FAF 0.00193551 (0.193551%).
  • The VCEP rule does not specify a non-cancer or exome-only population source, so the default all-comers gnomAD v4.1 entry was used.
Sources
PM3 VCEPNot met: the exact variant was heterozygous in a leukemia patient, with paternal inheritance and no reported A-T diagnosis or pathogenic ATM variant in trans. Details ▾Hide ▴
Reasoning

The governing ATM VCEP PM3 rule requires a recessive-disease observation in trans with a pathogenic variant and assigns points per unrelated A-T proband. The exact-variant report in Oguchi et al. (PMID:12511424) describes patient L-4 with heterozygous germline 8921C>T/p.Pro2974Leu inherited from the father, but the patient had MLL-rearranged childhood leukemia rather than an A-T diagnosis, and no pathogenic ATM variant in trans was reported. The ATM_PM3_BP2_1.6.pdf table contains no entry for c.8921C>T, p.Pro2974Leu, or p.P2974L. Therefore no PM3 points are assignable under the VCEP specification.

VCEP rule
For recessive disorders, detected in trans with a pathogenic variant ... Phenotypes associated with A-T are very specific and do not generally require differential diagnosis.
Evidence considered
  • ATM_PM3_BP2_1.6.pdf: the PM3 section requires detection in trans with a pathogenic variant and scores unrelated A-T probands; the table has no matching row for c.8921C>T, p.Pro2974Leu, or p.P2974L.
  • Oguchi et al., PMID:12511424, exact-variant report: patient L-4 had heterozygous germline 8921C>T/p.Pro2974Leu, inherited from the father; the report concerns MLL-rearranged childhood leukemia, not A-T, and does not report a pathogenic ATM variant in trans.
Still missing
  • No entry for c.8921C>T, p.Pro2974Leu, or p.P2974L was found in ATM_PM3_BP2_1.6.pdf; this file-search result is not evidence that allelic observations are absent elsewhere.
Sources
PP3 VCEPNot met: REVEL 0.148 is below the >0.7333 PP3 threshold and SpliceAI maximum delta 0.006 is below the >=0.2 threshold. Details ▾Hide ▴
Reasoning

The ATM VCEP PP3 rule applies to missense variants through REVEL >0.7333, or through the splicing path when SpliceAI is >=0.2 for silent, missense/in-frame, and qualifying intronic variants. This variant is missense, with REVEL 0.148 and SpliceAI maximum delta score 0.006; neither threshold is met. The exact Sun et al. Table S1 row for c.8921C>T/p.P2974L reports REVEL 0.148 and Classification Functional, Confidence High, DeepATM_predicted No; the latter functional classification is not used as computational predictor evidence for PP3.

VCEP rule
* Missense: REVEL **>.7333** * Splicing: Predicted impact via splicing (SpliceAI **≥0.2**) for silent, missense/in-frame and for intronic variants outside of donor and acceptor 1,2 sites.
Evidence considered
  • The ATM VCEP PP3 rule states: missense REVEL >0.7333; alternatively, predicted splicing impact via SpliceAI >=0.2 applies to silent, missense/in-frame, and qualifying intronic variants.
  • Local REVEL lookup for NM_000051.4:c.8921C>T, p.(Pro2974Leu) reports score 0.148.
  • SpliceAI reports DS_AG 0.001, DS_AL 0.006, DS_DG 0.0, and DS_DL 0.002, with maximum delta score 0.006.
  • Sun et al. 2025 Supplementary Table S1, exact row c.8921C>T / P2974L / exon_62: REVEL 0.148; Classification Functional; Confidence High; DeepATM_predicted No.
Sources
BA1 VCEPNot met: gnomAD v4.1 grpmax Filtering AF is 0.193551%, below the VCEP BA1 threshold of >0.5%. Details ▾Hide ▴
Reasoning

The ATM VCEP defines BA1 as Grpmax Filtering AF >.5% in gnomAD. Using the default all-comers gnomAD source because the VCEP does not specify a non-cancer or exome-only source, the highest applicable grpmax Filtering AF is 0.00193551 (0.193551%) in gnomAD v4.1, which is below 0.5%; therefore BA1 is not met.

VCEP rule
Grpmax Filtering AF **>.5%** in gnomAD
Evidence considered
  • ClinGen HBOP ATM VCEP v1.6 CSPEC BA1 rule: Grpmax Filtering AF >.5% in gnomAD.
  • gnomAD v4.1 all-comers: grpmax FAF 0.00193551 (0.193551%); highest subpopulation East Asian AF 0.0022949066440889443 (0.22949%), 103/44882 alleles, homozygotes 0.
  • The VCEP rule does not specify a non-cancer or exome-only population source, so the default all-comers gnomAD v4.1 entry was used.
Sources
BP2 VCEPNot met: no cis or trans pathogenic-variant observation in an unaffected adult was reported for this heterozygous variant. Details ▾Hide ▴
Reasoning

The governing ATM VCEP BP2 rule permits evidence from a variant observed in trans with a pathogenic variant for a fully penetrant dominant disorder or in cis with a pathogenic variant, and its ATM downgrade path requires an unaffected individual aged 18 years or older with no evidence of A-T. The exact-variant report in Oguchi et al. (PMID:12511424) documents the variant as heterozygous and inherited from the father in an affected child; it does not establish cis with a pathogenic variant, trans with a pathogenic variant, or an unaffected adult proband. The ATM_PM3_BP2_1.6.pdf table contains no entry for c.8921C>T, p.Pro2974Leu, or p.P2974L. Therefore BP2 is not met.

VCEP rule
Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern. ... When assessing homozygous or in trans variants (with a likely pathogenic or pathogenic ATM variant) for possible downgrade in an unaffected individual, the individual should be 18 years or older with no evidence of A-T.
Evidence considered
  • ATM_PM3_BP2_1.6.pdf: BP2 covers observation in trans with a pathogenic variant for a fully penetrant dominant disorder or in cis with a pathogenic variant; its ATM downgrade note requires an unaffected individual aged 18 years or older with no evidence of A-T. The table has no matching row for c.8921C>T, p.Pro2974Leu, or p.P2974L.
  • Oguchi et al., PMID:12511424, exact-variant report: patient L-4 was a heterozygous germline carrier with paternal inheritance and childhood leukemia; no cis/trans pathogenic-variant relationship or qualifying unaffected adult proband was reported.
Still missing
  • No entry for c.8921C>T, p.Pro2974Leu, or p.P2974L was found in ATM_PM3_BP2_1.6.pdf; this file-search result is not evidence that allelic observations are absent elsewhere.
Sources
Not applicable · 17· recorded as not applicable Show reasons ▾Hide reasons ▴
PVS1 N/ANot applicable: c.8921C>T is a missense SNV (p.Pro2974Leu) in exon 62, not a PVS1 null-variant class. Details ▾Hide ▴
Reasoning

The queried variant is NM_000051.4:c.8921C>T, NP_000042.3:p.(Pro2974Leu), a missense SNV in exon 62, as shown by the exact matching row in Sun et al. 2025 Supplementary Table S1. The ATM VCEP PVS1 rule is for null variants (nonsense, frameshift, canonical +/-1 or 2 splice sites, initiation codon, or single/multi-exon deletion) in a gene where loss of function is a known disease mechanism. This missense substitution is outside the PVS1 variant classes, so PVS1 is not applicable; no strength tier is assigned.

VCEP rule
PVS1 Null variant (nonsense, frameshift, canonical +/-1 or 2 splice sites, initiation codon, single or multi-exon deletion) in a gene where loss of function (LOF) is a known mechanism of disease
Evidence considered
  • Sun et al. 2025 Supplementary Table S1, exact row: hg38 position 108365152 C>T; c.8921C>T; P2974L; exon_62; variant consequence Missense; amino-acid residue 2974; Classification Functional; Confidence High; DeepATM_predicted No.
  • ATM_PVS1_1.6.pdf, page 1: PVS1 is defined for null variants including nonsense, frameshift, canonical +/-1 or 2 splice sites, initiation codon, and single or multi-exon deletion in a gene where loss of function is a known mechanism of disease.
  • ATM_PVS1_1.6.pdf.txt was searched for c.8921C>T, p.Pro2974Leu, and p.P2974L; no variant-specific entry was found.
Still missing
  • No entry for c.8921C>T, p.Pro2974Leu, or p.P2974L was found in ATM_PVS1_1.6.pdf.txt; that VCEP file was searched explicitly.
Sources
PS2 VCEPNot applicable: the ATM VCEP marks PS2 not applicable, and the variant-specific report documents paternal inheritance rather than a de novo event. Details ▾Hide ▴
Reasoning

The ATM VCEP specification explicitly marks PS2 as not applicable. The available variant-specific report describes paternal inheritance rather than a de novo event: the father was heterozygous for the same allele.

VCEP rule
Not Applicable
Evidence considered
  • ATM VCEP v1.6 CSPEC criterion entry: PS2 applicability is "Not Applicable".
  • Oguchi et al. (PMID:12511424), Results, "Nucleotide change of the ATM gene": patient L-4 carried heterozygous ATM 8921C>T and the variant was inherited from her father; the father was heterozygous for the variant.
Sources
PM1 VCEPNot applicable: the ATM VCEP explicitly marks PM1 as Not Applicable, and no authoritative ATM domain-table entry is present. Details ▾Hide ▴
Reasoning

The ATM VCEP CSPEC entry explicitly marks PM1 as Not Applicable. The case vcep_materials.json domain_tables key is empty, so there is no authoritative approved ATM domain list that can create an alternate PM1 route.

VCEP rule
Not Applicable
Evidence considered
  • ATM VCEP CSPEC criteria entry for PM1: applicability is Not Applicable.
  • vcep_materials.json domain_tables is empty; no approved ATM critical-domain list is available for a separate PM1 assessment.
Sources
PM4 N/ANot applicable: the variant is a missense substitution, whereas the ATM VCEP limits PM4 to stop-loss variants. Details ▾Hide ▴
Reasoning

The exact VCEP table row classifies c.8921C>T, p.P2974L as a missense SNV in exon 62. The ATM VCEP PM4 rule is limited to stop-loss variants. Because this variant is a missense substitution and does not abolish the normal termination codon, PM4 is not applicable.

VCEP rule
Use for stop-loss variants.
Evidence considered
  • Sun et al. 2025 Supplementary Table S1, exact row for c.8921C>T/P2974L: exon_62 and Missense.
  • ATM VCEP v1.6 CSPEC PM4 entry: the criterion is for stop-loss variants.
Sources
PM5 N/ANot applicable: PM5 is limited to NMD-prone truncating variants with PVS1 Very Strong and premature termination codons upstream of p.Leu3048, whereas this is missense. Details ▾Hide ▴
Reasoning

The ATM VCEP PM5 rule applies to NMD-prone truncating DNA or splice variants receiving PVS1 at Very Strong with premature termination codons upstream of p.Leu3048. c.8921C>T is a missense variant producing p.Pro2974Leu, not a qualifying truncating or premature-termination variant.

VCEP rule
* DNA Variants: Apply to all NMD-prone, truncating variants receiving PVS1 (must be at VeryStrong) with premature termination codons upstream of p.Leu3048 ... * Splice Variants: Apply only to observed (not predicted) NMD-prone, truncating variants receiving PVS1(RNA) (must be at VeryStrong with high-quality RNA data) with premature termination codons upstream of p.Leu3048. This is not applicable for predicted splice impact without RNA data or PVS1(RNA) at reduced strength.
Evidence considered
  • ATM VCEP CSPEC PM5 rule: DNA variants must be NMD-prone truncating variants with PVS1 at Very Strong and premature termination codons upstream of p.Leu3048; the splice path has the analogous PVS1(RNA) requirement.
  • The case normalization identifies NM_000051.4:c.8921C>T as NP_000042.3:p.(Pro2974Leu), a missense substitution.
Sources
PM6 VCEPNot applicable: the ATM VCEP marks PM6 not applicable, and the reported variant was inherited from a heterozygous father. Details ▾Hide ▴
Reasoning

The ATM VCEP specification explicitly marks PM6 as not applicable. The available variant-specific report documents inheritance from a heterozygous father, not an apparently de novo occurrence.

VCEP rule
Not Applicable
Evidence considered
  • ATM VCEP v1.6 CSPEC criterion entry: PM6 applicability is "Not Applicable".
  • Oguchi et al. (PMID:12511424), Results and Discussion: the patient's father carried the same heterozygous 8921C>T allele, excluding an apparently de novo interpretation for this report.
Sources
PP1 N/ANot applicable: the VCEP limits PP1 to autosomal-recessive segregation in affected relatives, while this report shows paternal inheritance without qualifying affected-relative segregation. Details ▾Hide ▴
Reasoning

The ATM VCEP specifies PP1 only for its listed autosomal-recessive segregation conditions: one, two, or at least three affected relatives. This case concerns a heterozygous ATM variant in an ATM-related cancer predisposition context, and the cited report documents paternal inheritance without affected-relative segregation.

VCEP rule
AR Condition: Segregation in ≥3 affected relatives ... AR Condition: Segregation in 2 affected relatives ... AR Condition: Segregation in 1 affected relative
Evidence considered
  • ATM VCEP v1.6 CSPEC PP1 rule: supporting for segregation in 1 affected relative, moderate for 2 affected relatives, and strong for at least 3 affected relatives under the AR condition.
  • Oguchi et al. (PMID:12511424): the variant was inherited from the heterozygous father; the father remained free of malignant disease at publication, so no qualifying affected-relative segregation is reported.
Sources
PP2 VCEPNot applicable: the ATM VCEP explicitly marks PP2 as Not Applicable, so no gene-level missense-mechanism evidence can be assigned under this framework. Details ▾Hide ▴
Reasoning

The ATM VCEP CSPEC entry explicitly marks PP2 as Not Applicable. No generic gene-level missense mechanism or alternate PP2 threshold may be substituted under the VCEP-only instruction.

VCEP rule
Not Applicable
Evidence considered
  • ATM VCEP CSPEC criteria entry for PP2: applicability is Not Applicable.
Sources
PP4 VCEPNot applicable: the ATM VCEP explicitly marks PP4 as Not Applicable. Details ▾Hide ▴
Reasoning

The ATM VCEP CSPEC explicitly marks PP4 as Not Applicable. No phenotype-specific PP4 assessment is therefore permitted under this governing framework.

VCEP rule
Not Applicable
Evidence considered
  • ClinGen HBOP ATM VCEP v1.6 CSPEC PP4 entry: Not Applicable.
Sources
PP5 VCEPNot applicable: the ATM VCEP explicitly marks PP5 as Not Applicable. Details ▾Hide ▴
Reasoning

The ATM VCEP CSPEC explicitly marks PP5 as Not Applicable. Published assertions or other laboratory classifications cannot be used for PP5 under this governing framework.

VCEP rule
Not Applicable
Evidence considered
  • ClinGen HBOP ATM VCEP v1.6 CSPEC PP5 entry: Not Applicable.
Sources
BS2 VCEPNot applicable: the ATM VCEP says not to use BS2 because ATM has incomplete penetrance. Details ▾Hide ▴
Reasoning

The ATM VCEP explicitly instructs that BS2 is not applicable because ATM has incomplete penetrance; no BS2 evidence was assessed.

VCEP rule
Do not use: ATM has incomplete penetrance.
Evidence considered
  • ClinGen HBOP ATM VCEP v1.6 CSPEC BS2 applicability and instruction: Do not use: ATM has incomplete penetrance.
Sources
BS4 VCEPNot applicable: the ATM VCEP marks BS4 not applicable, despite the heterozygous father being free of malignant disease at publication. Details ▾Hide ▴
Reasoning

The ATM VCEP specification explicitly marks BS4 as not applicable. Although the variant-specific report notes that the heterozygous father remained free of malignant disease, that observation cannot be assigned BS4 under this VCEP rule set.

VCEP rule
Not Applicable
Evidence considered
  • ATM VCEP v1.6 CSPEC criterion entry: BS4 applicability is "Not Applicable".
  • Oguchi et al. (PMID:12511424), Discussion: "The father, however, remains free from malignant disease to date."
Sources
BP1 VCEPNot applicable: the ATM VCEP explicitly marks BP1 as Not Applicable, so no generic benign missense-location evidence can be assigned. Details ▾Hide ▴
Reasoning

The ATM VCEP CSPEC entry explicitly marks BP1 as Not Applicable. No generic benign missense-location rule may be substituted under the VCEP-only instruction.

VCEP rule
Not Applicable
Evidence considered
  • ATM VCEP CSPEC criteria entry for BP1: applicability is Not Applicable.
Sources
BP3 VCEPNot applicable: the ATM VCEP v1.6 CSPEC explicitly marks BP3 as Not Applicable for this assessment framework. Details ▾Hide ▴
Reasoning

The ATM VCEP v1.6 CSPEC entry explicitly marks BP3 as Not Applicable. The exact VCEP functional table row independently identifies this variant as a missense SNV in exon 62, so BP3 is not applied.

VCEP rule
Not Applicable
Evidence considered
  • ATM VCEP v1.6 CSPEC BP3 entry: applicability is Not Applicable.
  • Sun et al. 2025 Supplementary Table S1, exact row for c.8921C>T/P2974L: variant consequence Missense and exon_62.
Sources
BP5 VCEPNot applicable: the ATM VCEP explicitly marks BP5 as Not Applicable. Details ▾Hide ▴
Reasoning

The ATM VCEP CSPEC explicitly marks BP5 as Not Applicable. No BP5 evaluation is permitted under this governing framework.

VCEP rule
Not Applicable
Evidence considered
  • ClinGen HBOP ATM VCEP v1.6 CSPEC BP5 entry: Not Applicable.
Sources
BP6 VCEPNot applicable: the ATM VCEP explicitly marks BP6 as Not Applicable. Details ▾Hide ▴
Reasoning

The ATM VCEP CSPEC explicitly marks BP6 as Not Applicable. Published benign assertions or other laboratory classifications cannot be used for BP6 under this governing framework.

VCEP rule
Not Applicable
Evidence considered
  • ClinGen HBOP ATM VCEP v1.6 CSPEC BP6 entry: Not Applicable.
Sources
BP7 N/ANot applicable: p.Pro2974Leu is a missense substitution, whereas BP7 is limited to synonymous or deep intronic variants. Details ▾Hide ▴
Reasoning

The ATM VCEP BP7 rule applies to synonymous and deep intronic variants, and separately describes observed RNA evidence for silent substitutions and intronic variants. NM_000051.4:c.8921C>T, p.(Pro2974Leu), is an exonic missense substitution in exon 62, so it lies outside BP7's named variant scope and no computational or RNA evidence is evaluated for BP7.

VCEP rule
* BP7: Use for synonymous and deep intronic variants defined as further than (but not including) +7 and further than (but not including) -21 at donor and acceptor sites, respectively. * BP7(RNA): Observed lack of aberrant RNA defect for silent substitutions and intronic variants. Variable weight applied depending on curator discretion of assay quality.
Evidence considered
  • The ATM VCEP BP7 rule applies to synonymous and deep intronic variants, with BP7(RNA) addressing observed lack of aberrant RNA defect for silent substitutions and intronic variants.
  • Variant assessment identifies NM_000051.4:c.8921C>T as an exonic missense variant in exon 62 with predicted protein change p.(Pro2974Leu).
Sources
cspec ↗pvs1_variant_assessment

Identifiers

Gene
ATM
Transcript
NM_000051.4
Coding (HGVS c.)
NM_000051.4:c.8921C>T
Protein (HGVS p.)
NP_000042.3:p.(Pro2974Leu)
GRCh38
chr11:108365152 C>T
GRCh37
chr11:108235879 C>T
Location and type
Exon 62 · missense
ClinVar
135787
COSMIC
COSV99069711

Gene diagram

Every interpreted variant in ATM, mapped onto the exon structure of NM_000051.4. Select a row to find it on the plot.

ATMNM_000051.4
Fetching transcript structure from UCSC…
gnomAD v4.1 158 / 1,614,118 alleles AF 9.79e-05 · 0 homozygotes · FAF 0.00194
gnomAD v2.1 22 / 282,796 alleles AF 7.78e-05 · 0 homozygotes · FAF 0.000178
gnomAD-Canada v1.0 Allele count data not recorded

By genetic ancestry

gnomAD v4.1

AF 9.8e-05 · 158 / 1,614,118 alleles · 0 hom · FAF 0.0019
East Asian103 / 44,882 0.0023
Middle Eastern4 / 6,062 0.00066
African/African American12 / 75,026 0.00016
Remaining individuals4 / 62,506 6.4e-05
South Asian3 / 91,082 3.3e-05
European (non-Finnish)31 / 1,180,008 2.6e-05
Admixed American1 / 60,026 1.7e-05
0 alternate alleles recorded in 3 other groups: European (Finnish), Amish, Ashkenazi Jewish.

gnomAD v2.1

AF 7.8e-05 · 22 / 282,796 alleles · 0 hom · FAF 0.00018
East Asian8 / 19,952 0.0004
African/African American6 / 24,968 0.00024
European (non-Finnish)7 / 129,110 5.4e-05
South Asian1 / 30,614 3.3e-05
0 alternate alleles recorded in 4 other groups: Admixed American, Ashkenazi Jewish, European (Finnish), Remaining individuals.

gnomAD-Canada

AF not recorded · ? / ? alleles

Statements

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 9.78863e-05; MAF= 0.00979%, 158/1614118 alleles, homozygotes = 0) and has highest observed frequency in the East Asian population (AF= 0.00229491; MAF= 0.22949%, 103/44882 alleles, homozygotes = 0); grpmax FAF= 0.00193551.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 7.77946e-05; MAF= 0.00778%, 22/282796 alleles, homozygotes = 0) and has highest observed frequency in the East Asian population (AF= 0.000400962; MAF= 0.04010%, 8/19952 alleles, homozygotes = 0); grpmax FAF= 0.0001781.

gnomAD-Canada

This variant is present in gnomAD-Canada v1.0 (AF= 0.00016291951775822744, 3/18414 alleles, homozygotes = 0).

Open the gnomAD-Canada detail page →

SpliceAI and Pangolin

SpliceAI acceptor lossat -7 bp
0.006
SpliceAI acceptor gainat +173 bp
0.001
SpliceAI donor lossat +350 bp
0.002
SpliceAI donor gainat +371 bp
0.000
Pangolin splice lossmagnitude shown
-0.004
Pangolin splice gain
0.002

Other predictors

REVEL
0.148
BayesDel
-0.430

How the predictions were used

BP4 SupportingVCEPMet: missense REVEL 0.148 is at or below the VCEP BP4 cutoff of <=0.249. Details ▾Hide ▴
Reasoning

The ATM VCEP BP4 rule provides a missense path using REVEL <=0.249 and a splicing path using SpliceAI <=0.1. This is a missense variant with REVEL 0.148, which directly meets the VCEP missense cutoff; SpliceAI maximum delta score 0.006 also meets the VCEP no-predicted-splicing-impact cutoff. The evidence is counted once for BP4, using the named missense predictor as the decisive path. The exact Sun et al. Table S1 row for c.8921C>T/p.P2974L reports REVEL 0.148 and Classification Functional, Confidence High, DeepATM_predicted No; the functional classification is not treated as a separate BP4 prediction.

VCEP rule
* Missense: REVEL score **≤.249** * Splicing: No predicted impact via splicing (SpliceAI **≤0.1**).
Evidence considered
  • The ATM VCEP BP4 rule states: missense REVEL <=0.249; alternatively, no predicted splicing impact via SpliceAI <=0.1.
  • Local REVEL lookup for NM_000051.4:c.8921C>T, p.(Pro2974Leu) reports score 0.148, meeting the missense BP4 threshold.
  • SpliceAI reports maximum delta score 0.006, also meeting the VCEP no-predicted-impact threshold; this is corroborative and not double-counted with REVEL.
  • Sun et al. 2025 Supplementary Table S1, exact row c.8921C>T / P2974L / exon_62: REVEL 0.148; Classification Functional; Confidence High; DeepATM_predicted No.
Sources
PP3 VCEPNot met: REVEL 0.148 is below the >0.7333 PP3 threshold and SpliceAI maximum delta 0.006 is below the >=0.2 threshold. Details ▾Hide ▴
Reasoning

The ATM VCEP PP3 rule applies to missense variants through REVEL >0.7333, or through the splicing path when SpliceAI is >=0.2 for silent, missense/in-frame, and qualifying intronic variants. This variant is missense, with REVEL 0.148 and SpliceAI maximum delta score 0.006; neither threshold is met. The exact Sun et al. Table S1 row for c.8921C>T/p.P2974L reports REVEL 0.148 and Classification Functional, Confidence High, DeepATM_predicted No; the latter functional classification is not used as computational predictor evidence for PP3.

VCEP rule
* Missense: REVEL **>.7333** * Splicing: Predicted impact via splicing (SpliceAI **≥0.2**) for silent, missense/in-frame and for intronic variants outside of donor and acceptor 1,2 sites.
Evidence considered
  • The ATM VCEP PP3 rule states: missense REVEL >0.7333; alternatively, predicted splicing impact via SpliceAI >=0.2 applies to silent, missense/in-frame, and qualifying intronic variants.
  • Local REVEL lookup for NM_000051.4:c.8921C>T, p.(Pro2974Leu) reports score 0.148.
  • SpliceAI reports DS_AG 0.001, DS_AL 0.006, DS_DG 0.0, and DS_DL 0.002, with maximum delta score 0.006.
  • Sun et al. 2025 Supplementary Table S1, exact row c.8921C>T / P2974L / exon_62: REVEL 0.148; Classification Functional; Confidence High; DeepATM_predicted No.
Sources
BP7 N/ANot applicable: p.Pro2974Leu is a missense substitution, whereas BP7 is limited to synonymous or deep intronic variants. Details ▾Hide ▴
Reasoning

The ATM VCEP BP7 rule applies to synonymous and deep intronic variants, and separately describes observed RNA evidence for silent substitutions and intronic variants. NM_000051.4:c.8921C>T, p.(Pro2974Leu), is an exonic missense substitution in exon 62, so it lies outside BP7's named variant scope and no computational or RNA evidence is evaluated for BP7.

VCEP rule
* BP7: Use for synonymous and deep intronic variants defined as further than (but not including) +7 and further than (but not including) -21 at donor and acceptor sites, respectively. * BP7(RNA): Observed lack of aberrant RNA defect for silent substitutions and intronic variants. Variable weight applied depending on curator discretion of assay quality.
Evidence considered
  • The ATM VCEP BP7 rule applies to synonymous and deep intronic variants, with BP7(RNA) addressing observed lack of aberrant RNA defect for silent substitutions and intronic variants.
  • Variant assessment identifies NM_000051.4:c.8921C>T as an exonic missense variant in exon 62 with predicted protein change p.(Pro2974Leu).
Sources
cspec ↗pvs1_variant_assessment

Statement

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.01). REVEL score = 0.148. BayesDel score = -0.430012.

8 paper records listed. 3 cited in the classification.

Cited in the classification

  • Missense mutation and defective function of ATM in a childhood acute leukemia patient with MLL gene rearrangement.
    Oguchi K et al. · 2003 May 1
    The paper explicitly reports ATM 8921C>T, resulting in Pro2974Leu, in patient L-4. The variant was heterozygous and germline, located in the PI-3 kinase domain, and the study reported partial rescue of radiosensitivity and reduced p53-Ser15 phosphorylation. This exact-variant report does not provide a distinct previously established pathogenic comparator for PS1.
    → PS3 · supporting → BS3 · supporting Names this variant
    PMID 12511424 ↗
    Source detail
    L-4 was identified to have a nucleotide change of 8921C>T on one allele.

    Location Results, ‘Nucleotide change of the ATM gene’; ‘Biologic activity of 8921T ATM’

    Context Seven children with MLL-rearranged childhood leukemia were studied; ATM sequencing, familial testing, population screening, radiosensitivity, kinase, Western blot, and transfection assays were performed.

  • Discovery of a Pathogenic Variant rs139379666 (p. P2974L) in ATM for Breast Cancer Risk in Chinese Populations.
    The paper explicitly studied ATM rs139379666, the P2974L missense substitution, in Chinese breast-cancer case-control cohorts and functional assays. It reports impaired homologous-recombination repair and altered DNA-damage responses for P2974L, but this is the exact queried variant rather than a distinct reference variant for PS1.
    → PS3 · supporting → PS4 · strong → BS3 · supporting Names this variant
    PMID 31160347 ↗
    Source detail
    Our results showed that compared to the reference allele, the risk allele significantly disrupts the activity of homologous recombination (HR)-mediated double-strand breaks (DSB) repair efficiency.

    Location Abstract; Results, ‘The effects of the ATM missense variant (rs139379666, P2974L) on the activity of homologous recombination (HR)-mediated double-strand breaks (DSB) repair efficiency’

    Context Three Chinese case-control cohorts totaling 7,204 breast-cancer cases and 9,593 controls were analyzed, with ATM-knockdown and ATM-knockout cell functional assays and structural analysis.

  • Sun et al. 2025
    → BS3 · supporting
    PMID 40580951 ↗

Other recorded publications

  • Identification and characterization of polymorphic variations of the ataxia telangiectasia mutated (ATM) gene in childhood Hodgkin disease.
    Takagi M et al. · 2004
    No paper-specific finding is recorded.
    PMID 12969974 ↗
  • Alterations of DNA damage-response genes ATM and ATR in pyothorax-associated lymphoma.
    Liu A et al. · 2005
    The paper reports an ATM missense change affecting codon 2974, described as Pro-Leu and corresponding to the queried p.Pro2974Leu variant, in the Pal-1 lymphoma cell line. Functional findings were from a cell line carrying both ATM and ATR mutations and were not isolated to ATM p.Pro2974Leu alone.
    Names this variant
    PMID 15696190 ↗
    Quoted passage
    Missense mutations involved codons 213 (TTT-GTT; Phe-Val) and 2974 (CCG-CTG; Pro-Leu) in OPL-1 and Pal-1, respectively (Gene Bank accession number NM000051).

    Results, ‘Mutation Analysis of PAL Cell Lines,’ ATM gene; Table 3

  • Genome-wide testing of putative functional exonic variants in relationship with breast and prostate cancer risk in a multiethnic population.
    Haiman CA et al. · 2013
    No paper-specific finding is recorded.
    PMID 23555315 ↗
  • Evaluation of ultra-deep targeted sequencing for personalized breast cancer care.
    Harismendy O et al. · 2013
    No paper-specific finding is recorded.
    PMID 24326041 ↗
  • Patterns and functional implications of rare germline variants across 12 cancer types.
    Lu C et al. · 2015
    No paper-specific finding is recorded.
    PMID 26689913 ↗
  • Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history.
    Chaffee KG et al. · 2018
    No paper-specific finding is recorded.
    PMID 28726808 ↗
  • The emerging landscape of breast cancer susceptibility.
    No paper-specific finding is recorded.
    PMID 18163131 ↗

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 9.78863e-05; MAF= 0.00979%, 158/1614118 alleles, homozygotes = 0) and has highest observed frequency in the East Asian population (AF= 0.00229491; MAF= 0.22949%, 103/44882 alleles, homozygotes = 0); grpmax FAF= 0.00193551.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 7.77946e-05; MAF= 0.00778%, 22/282796 alleles, homozygotes = 0) and has highest observed frequency in the East Asian population (AF= 0.000400962; MAF= 0.04010%, 8/19952 alleles, homozygotes = 0); grpmax FAF= 0.0001781.

gnomAD-Canada

This variant is present in gnomAD-Canada v1.0 (AF= 0.00016291951775822744, 3/18414 alleles, homozygotes = 0).

ClinVar

This variant has been reported in ClinVar as Uncertain significance (13 clinical laboratories) and as Likely benign (3 clinical laboratories) and as Benign (2 clinical laboratories). (ClinVarID = 135787)

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.01). REVEL score = 0.148. BayesDel score = -0.430012.

Functional

OncoKB identified variant-specific curated literature and context relevant to functional review; biological-effect context: Likely Loss-of-function; curated oncogenicity label: Likely Oncogenic.

Somatic

This variant does not lie in a statistically significant hotspot. This variant has previously been reported in somatic cancers (COSMIC; COSV99069711, n = 8 times).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.